NCT03034200: Phase 2 Study of ONC201 in Neuroendocrine Tumors

NCT03034200
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: Neuroendocrine Tumor (NET)
Recruitment Status: Recruiting
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Must have diagnosis of neuroendocrine tumor
Exclusions: 
https://ClinicalTrials.gov/show/NCT03034200

Comments are closed.

Up ↑